Acalabrutinib significantly improved PFS compared with IR or BR and has an acceptable safety profile in patients with R/R CLL.

14 нояб. 2022 г. · ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator's choice of idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in ...

1 сент. 2020 г. · Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.

5 нояб. 2021 г. · Conclusions: At 3 years of follow-up, the efficacy of acala monotherapy was maintained, showing a significant PFS benefit over standard-of-care ...

23 нояб. 2021 г. · Conclusions: At 3 years of follow-up, the efficacy of acala monotherapy was maintained, showing a significant PFS benefit over standard-of-care ...

In the primary analysis of ASCEND, acalabrutinib monotherapy demonstrated significantly improved progression-free survival (PFS) with an acceptable tolerability ...

14 нояб. 2022 г. · In the primary ASCEND analysis (median 16.1-month follow-up), acalabrutinib showed superior efficacy with an acceptable tolerability profile ...

We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL) ...

ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic ...

12 авг. 2022 г. · The ASCEND trial was in the relapse setting, and it compared treatment with acalabrutinib vs what would be considered more active therapies: ...